A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs ACH 4471 (Primary)
- Indications Glomerulonephritis; Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 10 Jul 2018 According to an Achillion Pharmaceuticals media release, 14-day results from this study is anticipated in the third quarter of 2018.
- 30 Apr 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2018 to 1 May 2018.
- 12 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.